Events

EARMA and INORMS conference - a Sustainable profession in a sustainable world
MAY
Tue
06
MAY
Wed
07
MAY
Thu
08

Starts in 2 months from now

Location

FEMA Palacio Municipal, MAdrid, Spain

Programmes
Horizon Europe

The European Association of Research Managers and Administrators (EARMA) will host the next congress of  INORMS , the International Network of Research Management Societies.

More information is published on the EARMA event page

The conference theme is "a sustainable profession in a sustainable world". 

Following topics will be addressed:
       🔷 Building Better RMA Services
       🔷 Governance and Regulation
       🔷 Knowledge Valorisation
       🔷 Open Science
       🔷 Proposal, Award, and Project Management
       🔷 Responsible Use of AI in Research Management
       🔷 Transnational Collaborations
       🔷 Sustainability in RMA
       🔷 Responsibility, Ethics, and EDI in Research and Innovation

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.